辅助免疫检查点抑制剂治疗肢端黑色素瘤的获益研究
该研究基于法国RIC-Mel黑色素瘤数据库,纳入64例接受辅助免疫治疗与64例倾向性评分匹配的未治疗肢端黑色素瘤患者,发现辅助免疫治疗在无复发生存期(RFS)和无远处转移生存期(DMFS)上均无明确获益,且18.8%的患者出现3-4级免疫相关不良事件。
要点
- 辅助免疫治疗未显著改善肢端黑色素瘤患者的RFS或DMFS。
- 接受免疫检查点抑制剂治疗的患者中18.8%发生3-4级免疫相关不良事件。
- 需仔细权衡辅助免疫治疗的获益与风险,其他治疗策略需更大样本研究验证。
核心结论
- 辅助免疫治疗对肢端黑色素瘤患者的RFS和DMFS无明确获益,且伴有严重免疫相关不良事件风险。
研究设计与样本
- 研究基于法国RIC-Mel黑色素瘤数据库,纳入64例接受辅助免疫治疗的肢端黑色素瘤患者,并通过倾向性评分匹配选取64例未治疗患者作为对照。
主要发现
- 辅助免疫治疗组与未治疗组的RFS风险比HR=0.84(95%CI 0.534-1.324),DMFS风险比HR=0.94(95%CI 0.565-1.562)。
- 接受辅助免疫检查点抑制剂治疗的患者中,18.8%发生3-4级免疫相关不良事件。
关键数值与推荐
- RFS的HR=0.84(95%CI 0.534-1.324),DMFS的HR=0.94(95%CI 0.565-1.562)。
- 3-4级免疫相关不良事件发生率为18.8%。
临床怎么用
- 对于肢端黑色素瘤患者,启动辅助免疫治疗前应仔细评估获益与风险,包括RFS、DMFS及严重irAE发生率。
- 需考虑其他治疗策略,并在更大规模研究中验证辅助免疫治疗的潜在有限临床获益。
局限性
- 研究样本量较小(共128例),可能影响统计效能。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD). Responses to immunotherapy are correlated with mutational load, which, in turn, is correlated with high cumulative sun damage (CSD). This suggests that AM patients may have poor responses to immunotherapy. The clinical benefit and safety profile of adjuvant immunotherapies in AM treatment have not been fully investigated. OBJECTIVES: To investigate whether the use of adjuvant immunotherapy for treating patients with AM in Stages IIb, IIc, III and IV NED (no evidence of disease) improves distant metastasis-free survival. METHODS: Among the 1005 AM patients in the RIC-Mel melanoma database, 64 AM patients who were treated with adjuvant immunotherapy were included in this study. We then calculated a propensity score to make the adjuvant immunotherapy-treated (n = 64) group and the untreated group (n = 64) comparable in all respects. RESULTS: The use of adjuvant immunotherapy for treating AM offers no clear benefit in terms of relapse-free survival or distant metastasis-free survival (RFS: HR = 0.84 [0.534, 1.324, 95% CI] and DMFS: HR = 0.94 [0.565, 1.562, 95% CI]). Among the AM patients who received adjuvant immune checkpoint inhibitors (ICI), 18.8% experienced severe (Grades 3-4) immune-related adverse events. CONCLUSIONS: The benefit-risk balance must be carefully weighed, including the relapse-free survival (RFS), distant metastasis-free survival (DMFS) and rate of severe immune-related adverse events (irAE) occurrence. Other therapeutic strategies should be investigated in larger studies to confirm the potential limited clinical benefit of this treatment strategy. UNLABELLED: WHAT IS THE DISEASE?: Acral melanoma is a rare form of skin cancer that usually appears on the palms of the hands, soles of the feet or under the nails. Unlike most other melanomas, it is not linked to sun exposure. LOCATION OF THE STUDY: This research was carried out in France using information from a national melanoma database. AIM OF THE STUDY: We wanted to find out whether patients with acral melanoma benefit from adjuvant immunotherapy. This treatment, given after surgery, is designed to reduce the risk of the cancer returning. METHODOLOGY: We studied 128 patients with acral melanoma. Half of them (64 patients) received immunotherapy, while the other half did not. The two groups were matched so that they could be fairly compared. KEY FINDINGS: The use of immunotherapy did not show a clear improvement in preventing the cancer from coming back or spreading to other parts of the body. In addition, almost 1 in 5 patients receiving immunotherapy experienced serious adverse events caused by the treatment. CONCLUSIONS AND PRACTICAL IMPLICATIONS: For people with acral melanoma, adjuvant immunotherapy may not provide significant benefit and carries a risk of severe adverse events. Doctors and patients should carefully weigh the advantages and risks before starting this treatment.
引用
- Sanogo D, Levard R, Cassecuel J, et al. Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas. J Eur Acad Dermatol Venereol. 2025. PMID: 41277783. doi:10.1111/jdv.70136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。